From biopharmaceuticals to medical devices, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will he
Follow us
MedCity News

Repligen sees $150M Avitide acquisition as key to reaching gene therapy goals

$91,000,000 Post-IPO equity

Alpine raises $91M to fuel the Seattle biotech’s clinical trials for lupus and cancer

$50,000,000 Venture capital (Series A)
Forbes Tech

This Startup Just Raised $50 Million To Deliver Gene Therapies For Rare Diseases

$90,000,000 Venture capital (Series B)
MedCity News

Blood disorder biotech Disc Medicine gets $90M to bring two drugs into Phase 2

MedCity News

Pfizer commits $1B to Arvinas for share of protein degrading breast cancer drug

$80,000,000 Venture capital (Series D)
WSJ Venture Capital

Cancer Drugmaker Turnstone Biologics Raises $80 Million


Best in Tech Awards 2021: Delfi Diagnostics

$168,000,000 Venture capital (Series D)
WSJ Venture Capital

Crossover Health Raises $168 Million to Grow Primary-Health Services

$50,000,000 Venture capital (Series D)
SiliconANGLE , neurons.AI , neurons.AI

Telehealth startup TytoCare raises $50M in oversubscribed Series D round extension

$150,000,000 Venture capital (Series B)

Sequoia China Leads $150 Million Round In Drug Developer Visen Pharma – China Money Network

$100,000,000 Venture capital (Series A)

Delfi Diagnostics Nets $100M in Series A Financing, Plans Multi-Cancer Screening Test


Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early …

$123,000,000 Venture capital (Series D)
AVCJ , DealStreetAsia

Carlyle leads $123m Series D for China's Abbisko

$95,000,000 Venture capital (Series C)
Pulse 2.0

Biopharmaceutical Company Edgewise Therapeutics Closes $95 Million In Series C

Pulse 2.0

Arvinas Stock Price Doubled Today: Why It Happened

$100,000,000 Venture capital (Series C)
ChinaMoneyNetwork , DealStreetAsia

CAR-T Biotech Firm Gracell Completes $100 Million Round – China Money Network

MedCity News

Augmedix goes public through reverse merger

$45,000,000 Venture capital (Series D)

TigerConnect Closes $45M Series D Funding

$85,000,000 Venture capital (Series C)

Olema Oncology Raises $85M in Series C Financing

$64,000,000 Undisclosed

Galecto Raises US$64M in Funding